 Lisa Foster Sterigenics Vice President of SteriPro® Services Visit Website |
Lisa Foster began her medical device career at Sterigenics International in 1989 in Quality Assurance. In 1997, Ms. Foster was named Vice President of Quality Assurance for Sterigenics, the global leader in sterilization services becoming V.P. of SteriPro® Services.
Ms. Foster is an Executive Committee Member of the AAMI Sterilization Standards Board and Committee. She serves as Co-Chair and ISO delegate to AAMI/ISO/TC 198/WG2. She has served as co-chair for the AAMI Radiation Process Control Task Group, which developed TIR 29, Guide for Process Control in Radiation Sterilization.
|
Sterilization Q&A
-
Asked March 22nd, 2009
The greatest benefit of terminal sterilization is reducing the risk of a nonsterile product being released to the recipient of the product. Terminal sterilization, using any of the various methodologies (EtO, Radiation, Steam, Dry Heat), can be validated to provide a 10-6 sterility assurance level (SAL) for the products sterilized using terminal sterilization methods. When terminal sterilization is used in conjunction with aseptic manufacture, the risk of a nonsterile is even further reduced. This can be accomplished two ways: 1) terminal sterilization of key components prior to aseptic manufacture and 2) terminal sterilization of the whole product after aseptic manufacture.
